Engineered immune cells take on Hard-to-Treat digestive cancers
NCT ID NCT05539430
First seen Jan 04, 2026 · Last updated May 09, 2026 · Updated 16 times
Summary
This early-phase trial tests a new treatment called LB1908, which uses a patient's own immune cells (T-cells) engineered to recognize and attack cancer cells that have a protein called claudin 18.2 on their surface. The study includes adults with advanced stomach, gastroesophageal junction, esophageal, or pancreatic cancer that cannot be removed by surgery or has spread. The main goals are to find a safe dose and to see if the treatment can shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Duke University
Durham, North Carolina, 27705, United States
-
Fred Hutchinson Cancer Center
Seattle, Washington, 98109, United States
-
John Theurer Cancer Center at HackensackUMC
Hackensack, New Jersey, 07601, United States
-
Karmanos Cancer Institute
Detroit, Michigan, 48201, United States
-
Medical College of Wisconsin
Milwaukee, Wisconsin, 53226, United States
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
-
OHSU Knight Cancer Institute
Portland, Oregon, 97239, United States
-
Roswell Park Comprehensive Cancer Center
Buffalo, New York, 14263, United States
-
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee, 37232, United States
Conditions
Explore the condition pages connected to this study.